Home Featured Page 290

Featured

Latest

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

PT227- Dr. Anne Wagner – Couples Therapy, MDMA, and MAPS

PT226 – Veronika Gold & Harvey Schwartz from Polaris Insight Center

PT229 – Dr. Matthew Johnson – What is Consciousness?

Light Years – Film Screening and Panel Discussion

PT230 – Penny White of NeonMind Biosciences

DMT for Depression: Paving the Way for New Medicine

Changa vs. DMT: What You Need to Know

Is the DMT Experience a Hallucination?

1...289290291...296 Page 290 of 296

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

PT227- Dr. Anne Wagner – Couples Therapy, MDMA, and MAPS

PTSF 42

PT226 – Veronika Gold & Harvey Schwartz from Polaris Insight Center

PTSF 45

PT229 – Dr. Matthew Johnson – What is Consciousness?

Light Years – Film Screening and Panel Discussion

PT230 – Penny White of NeonMind Biosciences

DMT for Depression: Paving the Way for New Medicine

Changa vs. DMT: What You Need to Know

Is the DMT Experience a Hallucination?

EDITOR PICKS

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY